𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical Benefits and Economic Analysis of Pegylated Liposomal Doxorubicin/Vincristine/Dexamethasone Versus Doxorubicin/Vincristine/Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

✍ Scribed by Porter, Christopher A.; Rifkin, Robert M.

Book ID
119935990
Publisher
CIG Media Group, LP.
Year
2007
Tongue
English
Weight
139 KB
Volume
7
Category
Article
ISSN
1557-9190

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II clinical trial of arsenic triox
Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma
✍ C.C. Hofmeister; B. Jansak; N. Denlinger; E.H. Kraut; D.M. Benson; S.S. Farag πŸ“‚ Article πŸ“… 2008 πŸ› Elsevier Science 🌐 English βš– 90 KB

In patients with multiple myeloma, there is preclinical justification to combine arsenic trioxide (ATO and As 2 O 3 ) with DVd (Doxil TM , vincristine, and dexamethasone) for newly diagnosed patients. Eleven patients on this phase II trial received 0.15 mg/kg of ATO for five consecutive days followe

A Phase II trial of pegylated liposomal
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
✍ Mohamad A. Hussein; Laura Wood; Eric Hsi; Gordan Srkalovic; MaryAnn Karam; Paul πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 91 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Patients with multiple myeloma (MM) have increased bone marrow angiogenesis, a low plasma cell labeling index, and multidrug resistance (the primary cause of chemotherapy failure). MM patients receiving the vincristine, doxorubicin, and dexamethasone (VAD) regimen develop